Lipocine Inc.

LPCN

HealthcareBiotechnologyNASDAQ

$2.37

Market Cap: $12.91M

Lipocine Inc. (LPCN) Valuation Summary

Updated Apr 20, 2026 22:15

Model	Range	Fair Value	Upside
▸ Discounted Cash Flow
Revenue DCF 5Y	$0.95 – $13.50	$4.81	+109.0%
Revenue DCF 10Y	$0.13 – $3.76	$0.13	-94.1%
▸ Trading Multiples
EV/Revenue	$2.55 – $36.91	$3.00	+30.4%

Valuation History

DCF Analysis

Lipocine Inc. (LPCN) Revenue DCF (5Y)

REVENUE DCF FAIR VALUE

$0.13

Market Price

$2.37

Upside / Downside

-94.5%

Verdict

Overvalued

Using a Revenue DCF model with operating margin convergence from -524.7% to a target of 13.3% over 5 years, discounted at a WACC of 8.7%, Lipocine Inc. (LPCN) has an intrinsic value of $0.13 per share (range: $0.13 – $3.76).

Key Assumptions

Current Operating Margin

-524.7%

Target Operating Margin

13.3%

WACC

8.7%

Terminal Growth Rate

3.0%

Historical CapEx/Rev

6.9%

Target CapEx/Rev

6.0%

D&A/Revenue

1.3%

Tax Rate

7.5%

Operating margin fades linearly from the current level to the industry target over the 5-year projection. CapEx intensity fades from the historical average to a maintenance level (D&A × 1.5). Tax is only applied when operating income is positive (NOL shield).

Margin Convergence Projection

USD in millions. Mid-year discounting convention.

Year	Revenue	Growth	Op Margin	Op Income	NOPAT	CapEx	ΔNWC	FCFF	PV(FCFF)
2026	1	-67.1%	-417.1%	-3	-3	(0)	1	-4	-3
2027	1	67.7%	-309.5%	-3	-3	(0)	-0	-3	-3
2028	2	127.0%	-201.9%	-5	-5	(0)	-0	-5	-4
2029	9	244.7%	-94.3%	-8	-8	(1)	-1	-8	-6
2030	21	141.9%	13.3%	3	3	(1)	-1	3	2
2031	19	-10.0%	13.3%	2	2	(1)	0	1	1
2032	17	-10.0%	13.3%	2	2	(1)	0	1	1
2033	15	-10.0%	13.3%	2	2	(1)	0	1	1
2034	14	-10.0%	13.3%	2	2	(1)	0	1	0
2035	13	-5.9%	13.3%	2	2	(1)	0	1	0

Enterprise Value Bridge

Sum of PV(FCFF)-12

Terminal Value (Gordon Growth at 3.0%)16

PV of Terminal Value7

Enterprise Value-4

(–) Net Debt-5

Equity Value1

(÷) Shares Outstanding6

Fair Value per Share$0.13

Sensitivity Analysis — WACC × Target Operating Margin

WACC \ Target Op. Margin	7.3%	10.3%	13.3%	16.3%	19.3%
6.7%	$-1	$-0	$1	$2	$4
7.7%	$-1	$-0	$1	$2	$3
8.7%	$-2	$-1	$0	$1	$2
9.7%	$-2	$-1	$-0	$1	$1
10.7%	$-2	$-1	$-0	$0	$1

Current price: $2.37. Green = undervalued, Red = overvalued.

Working Capital Assumption

Net Working Capital is modeled at -11.1% of revenue (historical average of receivables + inventory − payables). Changes in NWC (ΔNWC) are computed year-over-year and subtracted from free cash flow.

Lipocine Inc. (LPCN) Revenue DCF (5Y)

REVENUE DCF FAIR VALUE

$4.81

Market Price

$2.37

Upside / Downside

+103.0%

Verdict

Undervalued

Key Assumptions

Current Operating Margin

-524.7%

Target Operating Margin

13.3%

WACC

8.7%

Terminal Growth Rate

3.0%

Historical CapEx/Rev

6.9%

Target CapEx/Rev

6.0%

D&A/Revenue

1.3%

Tax Rate

7.5%

Margin Convergence Projection

USD in millions. Mid-year discounting convention.

Year	Revenue	Growth	Op Margin	Op Income	NOPAT	CapEx	ΔNWC	FCFF	PV(FCFF)
2026	1	-67.1%	-417.1%	-3	-3	(0)	1	-4	-3
2027	1	67.7%	-309.5%	-3	-3	(0)	-0	-3	-3
2028	2	127.0%	-201.9%	-5	-5	(0)	-0	-5	-4
2029	9	244.7%	-94.3%	-8	-8	(1)	-1	-8	-6
2030	21	141.9%	13.3%	3	3	(1)	-1	3	2

Enterprise Value Bridge

Sum of PV(FCFF)-14

Terminal Value (Gordon Growth at 3.0%)53

PV of Terminal Value37

Enterprise Value22

(–) Net Debt-5

Equity Value27

(÷) Shares Outstanding6

Fair Value per Share$4.81

Sensitivity Analysis — WACC × Target Operating Margin

WACC \ Target Op. Margin	7.3%	10.3%	13.3%	16.3%	19.3%
6.7%	$5	$7	$9	$11	$14
7.7%	$3	$5	$6	$8	$10
8.7%	$2	$3	$5	$6	$8
9.7%	$1	$3	$4	$5	$6
10.7%	$1	$2	$3	$4	$5

Current price: $2.37. Green = undervalued, Red = overvalued.

Working Capital Assumption

Trading Multiples

Fair Value

$3.00

Market Price

$2.37

Upside / Downside

+26.6%

Verdict

Undervalued

Using the industry peer median EV/Revenue multiple (trailing + forward), Lipocine Inc. (LPCN) has a fair value of $3.00 based on 4 comparable companies in the Biotechnology industry.

EV/Revenue Valuation — Biotechnology

USD in millions except Fair Price. Subject company highlighted.

	Mkt Cap ($M)	Trailing EV/Revenue	Forward EV/Revenue
Lipocine Inc.LPCN	14	4.2x	12.8x
Adlai Nortye Ltd.ANL	519	103.9x	77.4x
OSR Holdings, Inc.OSRH	15	4.7x	4.0x
BioLineRx Ltd.BLRX	10	14.3x	11.4x
Ernexa Therapeutics Inc.ERNA	2	0.8x	0.0x
Industry Median		9.5x	7.7x
(*) Revenue		2	1
= Enterprise Value		19	5
(-) Net Debt		-5	-5
Equity Value		24	10
(/) Outstanding shares		6	6
Fair Price		$4	$2

Selected Fair Value (avg of trailing + forward)

$3.00

+26.6%

Disclaimer: Sweet Value Lab provides estimated intrinsic values for informational purposes only. This is not financial advice. All models rely on assumptions that may not reflect future performance. Always do your own research before making investment decisions.

Model

Range

Fair Value

Upside

▸ Discounted Cash Flow

Revenue DCF 5Y

$0.95 – $13.50

$4.81

+109.0%

Revenue DCF 10Y

$0.13 – $3.76

$0.13

-94.1%

▸ Trading Multiples

EV/Revenue

$2.55 – $36.91

$3.00

+30.4%

DCF Analysis

Lipocine Inc. (LPCN) Revenue DCF (5Y)

REVENUE DCF FAIR VALUE

$0.13

Market Price

$2.37

Upside / Downside

-94.5%

Verdict

Overvalued

Key Assumptions

Current Operating Margin

-524.7%

Target Operating Margin

13.3%

WACC

8.7%

Terminal Growth Rate

3.0%

Historical CapEx/Rev

6.9%

Target CapEx/Rev

6.0%

D&A/Revenue

1.3%

Tax Rate

7.5%

Margin Convergence Projection

USD in millions. Mid-year discounting convention.

Year	Revenue	Growth	Op Margin	Op Income	NOPAT	CapEx	ΔNWC	FCFF	PV(FCFF)
2026	1	-67.1%	-417.1%	-3	-3	(0)	1	-4	-3
2027	1	67.7%	-309.5%	-3	-3	(0)	-0	-3	-3
2028	2	127.0%	-201.9%	-5	-5	(0)	-0	-5	-4
2029	9	244.7%	-94.3%	-8	-8	(1)	-1	-8	-6
2030	21	141.9%	13.3%	3	3	(1)	-1	3	2
2031	19	-10.0%	13.3%	2	2	(1)	0	1	1
2032	17	-10.0%	13.3%	2	2	(1)	0	1	1
2033	15	-10.0%	13.3%	2	2	(1)	0	1	1
2034	14	-10.0%	13.3%	2	2	(1)	0	1	0
2035	13	-5.9%	13.3%	2	2	(1)	0	1	0

Enterprise Value Bridge

Sum of PV(FCFF)-12

Terminal Value (Gordon Growth at 3.0%)16

PV of Terminal Value7

Enterprise Value-4

(–) Net Debt-5

Equity Value1

(÷) Shares Outstanding6

Fair Value per Share$0.13

Sensitivity Analysis — WACC × Target Operating Margin

WACC \ Target Op. Margin	7.3%	10.3%	13.3%	16.3%	19.3%
6.7%	$-1	$-0	$1	$2	$4
7.7%	$-1	$-0	$1	$2	$3
8.7%	$-2	$-1	$0	$1	$2
9.7%	$-2	$-1	$-0	$1	$1
10.7%	$-2	$-1	$-0	$0	$1

Current price: $2.37. Green = undervalued, Red = overvalued.

Working Capital Assumption

Trading Multiples

Fair Value

$3.00

Market Price

$2.37

Upside / Downside

+26.6%

Verdict

Undervalued

Using the industry peer median EV/Revenue multiple (trailing + forward), Lipocine Inc. (LPCN) has a fair value of $3.00 based on 4 comparable companies in the Biotechnology industry.

EV/Revenue Valuation — Biotechnology

USD in millions except Fair Price. Subject company highlighted.

	Mkt Cap ($M)	Trailing EV/Revenue	Forward EV/Revenue
Lipocine Inc.LPCN	14	4.2x	12.8x
Adlai Nortye Ltd.ANL	519	103.9x	77.4x
OSR Holdings, Inc.OSRH	15	4.7x	4.0x
BioLineRx Ltd.BLRX	10	14.3x	11.4x
Ernexa Therapeutics Inc.ERNA	2	0.8x	0.0x
Industry Median		9.5x	7.7x
(*) Revenue		2	1
= Enterprise Value		19	5
(-) Net Debt		-5	-5
Equity Value		24	10
(/) Outstanding shares		6	6
Fair Price		$4	$2

Selected Fair Value (avg of trailing + forward)

$3.00

+26.6%